ORPN - Bioblast Pharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
+0.0473 (+4.96%)
At close: 3:24PM EST
Stock chart is not supported by your current browser
Previous Close0.9527
Bid0.00 x 4000
Ask0.00 x 2200
Day's Range0.9853 - 1.0899
52 Week Range0.9520 - 5.9900
Avg. Volume150,463
Market Cap3.359M
Beta (3Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateFeb 22, 2018 - Feb 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • ACCESSWIRE28 days ago

    Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.

  • ACCESSWIRE29 days ago

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • GlobeNewswire29 days ago

    Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

    Enlivex is developing a novel immunotherapy with a unique mode of action targeting clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis – which is the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases, as well as effective treatment of solid tumors via immune checkpoint reprogramming, increasing the efficacy of CAR-T, TCR and other anti-cancer therapies. Phase IIa clinical trial for the prevention of GvHD in matched-donor population successfully completed.  Initiation of Phase II clinical trial in sepsis expected in Q2-2019, and initiation of a Phase II clinical trial for treatment of steroid-refractory GvHD patients and a Phase II/III clinical trial for preventing GvHD in bone marrow transplantations are expected in Q4-2019.

  • Who Are The Top Investors In Bioblast Pharma Ltd (NASDAQ:ORPN)?
    Simply Wall St.7 months ago

    Who Are The Top Investors In Bioblast Pharma Ltd (NASDAQ:ORPN)?

    Today, I will be analyzing Bioblast Pharma Ltd’s (NASDAQ:ORPN) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...

  • Benzinga7 months ago

    Benzinga Pro's 6 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! athenahealth, Inc (NASDAQ: ATHN ) stock was trading ...

  • What Kind Of Risk Should You Expect For Bioblast Pharma Ltd (NASDAQ:ORPN)?
    Simply Wall St.8 months ago

    What Kind Of Risk Should You Expect For Bioblast Pharma Ltd (NASDAQ:ORPN)?

    If you are looking to invest in Bioblast Pharma Ltd’s (NASDAQ:ORPN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Should You Be Concerned About Bioblast Pharma Ltd’s (NASDAQ:ORPN) Investors?
    Simply Wall St.10 months ago

    Should You Be Concerned About Bioblast Pharma Ltd’s (NASDAQ:ORPN) Investors?

    I am going to take a deep dive into Bioblast Pharma Ltd’s (NASDAQ:ORPN) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...

  • Benzinga11 months ago

    ICYMI: Shutterfly Downgrade, BioBlast Price Action, Blockchain ETFs

    In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 17, 2018. Blockchain ETFs’ Inaugural Trading Session Wayne Duggan breaks down the arrival of new ETFs - Reality Shares ...